Fig 3. Progression-free survival curves according to potential predictive biomarkers for nivolumab.

Kaplan-Meier curves are shown for the patients with CD4⁺ high vs. low (A), CD8⁺ high vs. low (B), Foxp3⁺ high vs. low (C), CD3⁺ high vs. low (D), PD-L1 positive vs. negative (E) and PS 0, 1 vs. 2 (F).